IH Convidecia as Second Booster Dose Against Breakthrough Infections

Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections. A Randomized Observer-blind Controlled Trial.

This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent breakthrough infections among people with a sub-optimal immune response to the first booster dose.

These subjects will be randomized in a ratio of 1:1 to receive a second booster dose of IH Convidecia vaccine (treatment arm), or a second booster dose of mRNA vaccine BNT162b2 (Pfizer).

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH); Biological: mRNA vaccine BNT162b2 (Pfizer)

• Study Type: Interventional
• Enrollment (Actual): 540
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Xiaoyuan Zhao; Phone Number: 022-58213600-6051; Email: xiaoyuan.zhao@cansinotech.com

Study Locations

• Malaysia
  • Selangor Darul Ehsan
    • Ampang, Selangor Darul Ehsan, Malaysia, 68000
      • Hospital Ampang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participant is willing and able to give written informed consent for participation in the study.
• Male or Female, aged 18 years or above and in good health as determined by study clinician. Participants may have well controlled or mild-moderate comorbidity.
• Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation.
• In the Investigator's opinion, participant is able and willing to comply with all trial requirements.
• At least 16 weeks after first booster dose of vaccination.

Exclusion Criteria:

• Confirmed cases, suspected cases or asymptomatic cases of COVID-19.
• Self-reported history of SARS and MERS infection.
• Receipt of live attenuated vaccine within one month prior to vaccination and other vaccines within 14 days prior to vaccination.
• Receipt of any SARS-COV-2 vaccine after first dose of booster vaccination.
• Participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination.
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines.
• History of allergic disease or reactions likely to be exacerbated by any component of study vaccines.
• Any history of anaphylaxis.
• Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or continuous use of anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban), or prior history of significant bleeding or bruising following IM injections or venipuncture.
• Suspected or known current alcohol or drug dependency.
• Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
• Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed).
• Participant with life expectancy of less than 6 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ad5-nCoV-IH; Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose, will receive a second booster dose of IH Convidecia vaccine.	Biological: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH); Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
Active Comparator: mRNA vaccine BNT162b2 (Pfizer); Participates age 18 or older who have completed a course of primary and first booster vaccination at least 16 weeks before, and who have sub-optimal antibody response to the first booster dose,will receive a second booster dose of mRNA vaccine BNT162b2 (Pfizer).	Biological: mRNA vaccine BNT162b2 (Pfizer); Subjects will be randomized to receive a second booster dose of BNT162b2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Level of saliva IgA antibodies by ELISA.	28 days post booster vaccination
Level of serum functional neutralizing antibodies by cPass Genscript	28 days post booster vaccination
Level of serum Anti-Spike IgG by ELISA.	28 days post booster vaccination
Level of anti S-RBD IgG by ELISA.	28 days post booster vaccination
Level of serum Anti-Nucleocapsid IgG by ELISA.	28 days post booster vaccination
Baseline level of Anti-Ad5 antibodies by ChemiLuminescence.	Day 0
Level of pseudo neutralising antibodies against the wild-type original strain and Beta, Delta, Omicron and emerging VOCs by ELISA.	28 days post booster vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of solicited adverse events	Incidence of solicited adverse events post booster vaccination in all subjects.	14 days
Incidence of serious adverse events	Incidence of serious adverse events post booster vaccination in all subjects.	Up to 24 weeks
Incidence of adverse events of special interest (AESI)	Incidence of AESI post booster vaccination in all subjects.	Up to 24 weeks
Efficacy against COVID-19 infection and transmission	RT-PCR-confirmed Covid-19 breakthrough infection, whether symptomatic or not.	At least 14 days post booster dose.
Efficacy against COVID-19 infection and transmission	RT-PCR-confirmed Covid-19 secondary attack rate among household members after an index case is detected.	Within 7 days after the sample date of the index case.
Level of saliva IgA antibodies by ELISA.		14 days post booster vaccination
Level of serum functional neutralizing antibodies by cPass Genscript		14 days post booster vaccination
Level of serum Anti-Spike IgG by ELISA.		14 days post booster vaccination
Level of anti S-RBD IgG by ELISA.		14 days post booster vaccination
Level of T cell responses by Intracellular Cytokine Staining (Th1/Th2) in subgroup subjects.		Up to 24 weeks
Level of T cell response by Enzyme-linked Immunospot (Elispot) in subgroup subjects.		Up to 24 weeks

Collaborators and Investigators

• Sponsor: CanSino Biologics Inc.
• Investigators: Principal Investigator: Sharon Shi Min Ng, Hospital Ampang; Principal Investigator: Sunita Bavanandam, Kuala Lumpur General Hospital; Principal Investigator: Norliza Zainudin, Hospital Selayang

Study record dates

Study Major Dates

• Study Start (Actual): September 20, 2022
• Primary Completion (Actual): May 2, 2023
• Study Completion (Actual): May 2, 2023

Study Registration Dates

• First Submitted: August 22, 2022
• First Submitted That Met QC Criteria: August 24, 2022
• First Posted (Actual): August 26, 2022

Study Record Updates

• Last Update Posted (Actual): September 8, 2023
• Last Update Submitted That Met QC Criteria: September 7, 2023
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Safety; Immunogenicity; Inhaled; Convidecia
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Disease Attributes; Breakthrough Infections; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: CT 2022-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No